ArticleNeurology(R) neuroimmunology & neuroinflammation2021
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis.
Open access · goldAbstract read
In one paragraph
Article in Neurology(R) neuroimmunology & neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Genes, Gene Loci, and Their Impacts on the Immune System in the Development of Multiple Sclerosis: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- A Comprehensive Exploration of the Transcriptomic Landscape in Multiple Sclerosis: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Effects of Lycium barbarum polysaccharide on the activation of pathogenic CD4 + T cells in a mouse model of multiple sclerosis.Neural regeneration research · 2026Article
- The molecular architecture of severe pediatric traumatic brain injury: integrated omics reveal therapeutic pathways.Critical care (London, England) · 2025Observational
- The clinical relevance of hyper-reflective foci in the inner retina at the diagnosis of multiple sclerosis.Neurological research and practice · 2025Article
- Selective inhibition of mitochondrial Kv1.3 prevents and alleviates multiple sclerosis in vivo.EMBO molecular medicine · 2025Article
- Myeloid ZNRF1 suppresses autoimmune demyelination and neuroinflammation by regulating MHC-II-mediated T cell activation.Journal of neuroinflammation · 2025Article
- Multiple sclerosis and gut microbiota: Lachnospiraceae from the ileum of MS twins trigger MS-like disease in germfree transgenic mice-An unbiased functional study.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- B Cells Influence Encephalitogenic T Cell Frequency to Myelin Oligodendrocyte Glycoprotein (MOG)38-49 during Full-length MOG Protein-Induced Demyelinating Disease.ImmunoHorizons · 2024Article
- CD4Scientific reports · 2024Article
- Emerging role of extracellular vesicles in multiple sclerosis: From cellular surrogates to pathogenic mediators and beyond.Journal of neuroimmunology · 2023Review
- Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.Neurology · 2023Article
- Induction of antigen-specific tolerance by hepatic AAV immunotherapy regardless of T cell epitope usage or mouse strain background.Molecular therapy. Methods & clinical development · 2023Article
- Mimicking the brain: Epstein-Barr virus and foreign agents as drivers of neuroimmune attack in multiple sclerosis.Frontiers in immunology · 2023Review
- Women in the field of multiple sclerosis: How they contributed to paradigm shifts.Frontiers in molecular neuroscience · 2023Review
- The immunology of multiple sclerosis.Nature reviews. Immunology · 2022Review
- Toward identification of personalized immunological profiles in multiple sclerosis.Science advances · 2022Review
- Therapeutic Advances in Multiple Sclerosis.Frontiers in neurology · 2022Review
- Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis.Frontiers in neurology · 2022Article
- Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment.Frontiers in neurology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 3 countries.
Carolina CrucianiFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Marco PuthenparampilFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Paula Tomas-OjerFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Ivan JelcicFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.ORCID 0000-0002-6187-7098
Maria Jose DocampoFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Raquel PlanasFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Praveena ManogaranFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Roland OpferFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Carla WickiFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Markus ReindlFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.ORCID 0000-0003-2817-1402
Ilijas JelcicFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Andreas LutterottiFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Roland MartinFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria.
Mireia SospedraFrom the Neuroimmunology and MS Research (NIMS) (C.C., M.P., P.T.O., I.J., M.J.D., R.P., P.M., C.W., I.J., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich, Switzerland; Department of Neuroscience DNS (M.P.), University-Hospital of Padova, Italy; Jung Diagnostics GmbH (R.O.), HIP - Health Innovation Port, Germany; Department of Health Sciences and Technology (C.W.), ETH Zurich, Switzerland; and Clinical Department of Neurology (M.R.), Medical University of Innsbruck, Austria. mireia.sospedraramos@usz.ch.
University of Padua · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesEncouraged by the enormous progress that the identification of specific autoantigens added to the understanding of neurologic autoimmune diseases, we undertook here an in-depth study of T-cell specificities in the autoimmune disease multiple sclerosis (MS), for which the spectrum of responsible autoantigens is not fully defined yet. The identification of target antigens in MS is crucial for therapeutic strategies aimed to induce antigen-specific tolerance. In addition, knowledge of relevant T-cell targets can improve our understanding of disease heterogeneity, a hallmark of MS that complicates clinical management.
methodsThe proliferative response and interferon gamma (IFN-γ) release of CSF-infiltrating CD4
resultsBy testing CSF-infiltrating CD4 DISCUSSION: Our observations reveal an association between autoantigen reactivity and features of disease heterogeneity that strongly supports an important role of T-cell specificity in MS pathogenesis. These data have the potential to improve patient classification in clinical practice and to guide the development of antigen-specific tolerization strategies.
Indexed as
AdultFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisMyelin-Oligodendrocyte GlycoproteinT-Cell Antigen Receptor SpecificityT-LymphocytesMOG protein, humanMyelin-Oligodendrocyte Glycoprotein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.